Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News

Heron Therapeutics (HRTX) PT Raised to $66 at Needham & CompanyJune 21, 2018 3:48 PM Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ OpportunityJune 21, 2018 1:15 PM Heron Therapeutics (HRTX) PT Raised to $51 at JefferiesJune 21, 2018 11:39 AM Two More Positive HTX-011 Studies Supports Bullish Heron Therapeutics (HRTX) Thesis - Cantor FitzgeraldJune 21, 2018 10:47 AM Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISIJune 21, 2018 10:23 AM HTX-011 for Postoperative Pain Management Receives Breakthrough Therapy Designation from FDAJune 21, 2018 8:05 AM Heron Therapeutics (HRTX) Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast Augmentation Achieves Primary EndpointsJune 21, 2018 8:01 AM Heron Announces Positive Topline Results from Phase 2b Clinical Studies of HTX-011 in Total Knee Arthroplasty and Breast AugmentationJune 21, 2018 8:00 AM